Purple Biotech Total Debt vs. Price To Book
| PPBT Stock | ILA 4.80 0.20 4.00% |
For Purple Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Purple Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Purple Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Purple Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Purple Biotech over time as well as its relative position and ranking within its peers.
Purple |
Purple Biotech Price To Book vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. Purple Biotech is rated top company in total debt category among its peers. It also is considered to be number one stock in price to book category among its peers . The ratio of Total Debt to Price To Book for Purple Biotech is about 1,342,685 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Purple Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Purple Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Purple Total Debt vs. Competition
Purple Biotech is rated top company in total debt category among its peers. Total debt of Biotechnology industry is at this time estimated at about 74.84 Million. Purple Biotech claims roughly 804,000 in total debt contributing just under 2% to stocks in Biotechnology industry.
Purple Price To Book vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Purple Biotech |
| = | 804 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Purple Biotech |
| = | 0.60 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Purple Price To Book Comparison
Purple Biotech is currently under evaluation in price to book category among its peers.
Purple Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Purple Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Purple Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Purple Biotech's change in net profit over the period of time. It can combine multiple indicators of Purple Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel. PURPLE BIOTECH operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 13 people.
Purple Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Purple Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Purple Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Purple Biotech's important profitability drivers and their relationship over time.
Use Purple Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Purple Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Purple Biotech will appreciate offsetting losses from the drop in the long position's value.Purple Biotech Pair Trading
Purple Biotech Pair Trading Analysis
The ability to find closely correlated positions to Purple Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Purple Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Purple Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Purple Biotech to buy it.
The correlation of Purple Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Purple Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Purple Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Purple Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Purple Biotech position
In addition to having Purple Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Momentum Thematic Idea Now
Momentum
Large corporations operating in software, education, financial and car manufacturing industries. The Momentum theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Momentum Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Your Equity Center. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Purple Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Purple Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Purple Biotech's income statement, its balance sheet, and the statement of cash flows.